Introduction
Peripheral neuropathic pain induced by chemotherapy detrimentally impacts the lives of cancer patients and is one of the major side effects responsible for discontinuation of anticancer treatment (Windebank and Grisold, 2008) . To date, the mechanisms underlying chemotherapy-induced neuropathic pain remain poorly understood (Windebank and Grisold, 2008) . Additional challenges for the management of chemotherapy-induced neuropathy include limited efficacy and significant side effects of existing medications (Pachman et al., 2011) . Thus, identification of therapeutic strategies that are both safe and effective for managing chemotherapy-evoked neuropathic pain remains an unmet clinical need.
Cannabinoids produce antinociceptive effects in preclinical models of neuropathic pain (Guindon and Hohmann, 2009; Herzberg et al., 1997; Ibrahim et al., 2003; Pertwee, 2009; Schlosburg et al., 2009 ). However, unwanted psychotropic effects of cannabinoids limit their potential clinical use (Ben Amar, 2006; Dhopeshwarkar and Mackie, 2014; Pertwee, 2009) . Two major subtypes of cannabinoid receptors, CB 1 and CB 2 , are the key receptors responsible for the pharmacological effects of cannabinoids (Mackie, 2006) . Both CB 1 and CB 2 receptors are G-protein-coupled receptors (GPCRs) whose signaling pathways include inhibition of adenylyl cyclase and activation of mitogen-activated protein kinases (Mackie, 2006) . CB 1 receptors are predominantly located in the central nervous system (CNS), whereas CB 2 receptors are found primarily in the immune cells (Galiegue et al., 1995; Marsicano and Lutz, 1999; Onaivi et al., 2006; Schatz et al., 1997) and are upregulated in the CNS in response to inflammation or injury (Maresz et al., 2005; Zhang et al., 2003) . Evaluation of the MOL #98483 6 receptor mechanisms underlying therapeutic and psychotropic effects of cannabinoids, following both acute and chronic administration, may facilitate the development of safe and effective cannabinoid-based pharmacotherapies (Ben Amar, 2006; Pertwee, 2009 ).
CP55,940 is a potent non-selective synthetic cannabinoid that has similar affinity for both CB 1 and CB 2 receptors in vitro (Abood et al., 1997; Felder et al., 1995; Griffin et al., 2000) . Whereas CB 2 agonists exhibit strong ligand-biased selectivity for different signal transduction pathways (Atwood et al., 2012) , CP55,940 is a balanced agonist that has not been found to show functional selectivity at CB 1 or CB 2 (Atwood et al., 2012; Howlett et al., 2002) . Thus, CP55,940, used in combination with CB 1 knockout (CB 1 KO) and CB 2 knockout (CB 2 KO) mice, represents a useful pharmacological tool for studying the functions of CB 1 and CB 2 receptors in vivo. CP55,940 has been reported to possess antinociceptive efficacy in various preclinical pain models, including acute pain, inflammatory pain, and neuropathic pain induced by traumatic nerve injury (Choong et al., 2007; Hohmann et al., 1999; Lichtman and Martin, 1997; Romero et al., 2002; Sain et al., 2009; Scott et al., 2004) . Pharmacological antagonism of CB 1 receptors alone (Choong et al., 2007; Lichtman and Martin, 1997; Romero et al., 2002) or of both CB 1 and CB 2 receptors (Scott et al., 2004) blocks the antinociceptive effects of CP55,940 in rats. However, a study using CB 1 KO and CB 2 KO mice reported that the antinociceptive effects of systemic CP55,940 (at 0.3 mg/kg i.p.), administered acutely, is mediated by CB 1 , but not CB 2 receptors (Sain et al., 2009) . This finding has led to the conclusion that agonist activity at CB 2 is not relevant to antinociceptive effects of mixed CB 1 /CB 2 agonists, at least following systemic administration. By contrast, we hypothesized that, due to the abundance of CB 1 receptors (relative to CB 2 receptors) in the CNS, higher
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Molecular Pharmacology Fast Forward. Published on April 22, 2015 as DOI: 10.1124 at ASPET Journals on June 19, 2017 molpharm.aspetjournals.org Downloaded from doses of mixed cannabinoids are required to activate CB 2 receptors (compared to the dose that is sufficient to activate CB 1 ) and that CB 2 -mediated antinociceptive effects, rather than being absent, are masked by CB 1 -mediated catatonia associated with mixed cannabinoid agonists. The differences between the in vitro and in vivo profiles of CP55,940 raise questions on differential roles and functions of CB 1 and CB 2 receptors in vivo, particularly in persistent pain states in which chronic dosing is required for clinical use.
In the present study, we investigated the contribution of cannabinoid CB 1 and CB 2 receptor subtypes to the in vivo actions of the mixed cannabinoid CP55,940 in a mouse model of chemotherapy-induced neuropathy using transgenic (i.e., CB 1 KO, CB 2 KO) and wildtype (WT) mice. We evaluated antinociceptive effects, possible tolerance, and typical CNS-associated side effects (i.e., hypothermia, catalepsy, and physical withdrawal) following chronic administration of CP55,940 at multiple doses.
Importantly, CB 1 KO mice were used to test the hypothesis that CB 2 -mediated signaling can be engaged by mixed cannabinoids in vivo to produce sustained anti-allodynic efficacy without producing side effects. Thus, under conditions in which confounding effects of CP55,940 at CB 1 receptors are absent (i.e., in CB 1 KO mice), CB 2 -mediated effects can be fully characterized to ascertain the therapeutic potential of targeting CB 2 receptors.
Materials and Methods

Subjects
Adult CB 1 KO and WT littermates on a CD1 background, and adult CB 2 KO and WT littermates on a C57BL/6J background, weighing 26-35 g and of both sexes, were MOL #98483 8 used in these experiments. CB 2 KO (B6.129P2-CNR2(tm1Dgen/J)) and corresponding WT (C57BL/6J) mice were originally purchased from Jackson Laboratory (ME, USA). CB 1 KO mice were generated as previously described (Ledent et al., 1999) , whereas corresponding WT littermates were periodically outcrossed with CD1 mice (strain #022) from Charles River Laboratories (MA, USA) to maintain genetic diversity. Animals were single housed in a temperature-controlled facility (73 ± 2 °F, 45% humidity, regular 12 h light/dark cycle, lights on at 7 am), with food and water ad libitum provided. All experimental procedures were approved by the Bloomington Institutional Animal Care and Use Committee of Indiana University and followed the guidelines of the International Association for the Study of Pain (Zimmermann, 1983) .
Drugs and chemicals
Paclitaxel was purchased from Tecoland Corporation (NJ, USA) and was dissolved in cremophor-vehicle (1:1:18 ratio of cremophor ® EL/ethanol/saline).
Cremophor ® EL, ethanol, dimethyl sulfoxide (DMSO), and acetone were purchased from Sigma-Aldrich (MO, USA). Alkamuls EL-620 was obtained from Rhodia (NJ, USA).
Saline was purchased from Aqualite System (IL, USA). (-)-CP55,940 (CP55,940) (Compton et al., 1992) was provided by the National Institute on Drug Abuse (NIDA, MD, USA) or purchased from Santa Cruz Biotechnology (TX, USA). Rimonabant (SR141716A) (Yoshioka et al., 1989) was provided by NIDA. AM630 (Ross et al., 1999) was purchased from Cayman Chemical Company (MI, USA). CP55,940, rimonabant, and AM630 were dissolved in vehicle (5:2:2:16 ratio of DMSO /alkamuls EL-620/ ethanol/ saline) and were administered intraperitoneally (i.p.) to mice in a volume of 5 ml/kg.
General experimental protocol
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Assessment of mechanical allodynia
Withdrawal thresholds (g) to mechanical stimulation were measured in duplicate for each paw using an electronic von Frey anesthesiometer supplied with a 90-gram range probe (IITC Life Science Inc., CA, USA) as described previously (Deng et al., 2012) .
Briefly, mice were individually placed in transparent plastic chambers on an elevated metal mesh table and were habituated to the testing apparatus for 30 min prior to testing.
When animals ceased exploratory behaviors, a force was applied to the midplantar region
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Assessment of cold allodynia
Response time (s) to cold stimulation was assessed in triplicate for each paw by the acetone method as described previously (Deng et al., 2015) . Briefly, Mice were individually placed underneath transparent plastic chambers on an elevated metal mesh table. After habituation, an acetone bubble that formed at the end of a blunt one ml syringe was gently presented onto the plantar surface of the hind paw. Time that the animal spent attending to (i.e., elevating, licking, biting, or shaking) the acetonestimulated paw was measured over a 60-second observation period.
Evaluation of cannabinoid withdrawal symptoms
WT mice were treated chronically with vehicle or CP55,940 (0.3 mg/kg/day i.p.)
for 9 days. CB 1 KO mice were treated chronically with vehicle or CP55,940 (0.3 or 3 mg/kg/day i.p.) for 9 days. On treatment day 9, at 30 min post final treatment injection, animals were first challenged with vehicle, and 30 min later challenged with the CB 1 antagonist rimonabant (10 mg/kg i.p.). Mice were video-recorded, and the numbers of paw tremors, headshakes, and scratching bouts were scored over 30 min following each challenge by an experimenter blinded to experimental conditions, as previously described (Cook et al., 1998; Deng et al., 2015) .
Rectal temperature
Rectal temperature (°C) was measured using a thermometer (Physitemp Instruments Inc., NJ, USA) equipped with a mouse rectal probe (Braintree Scientific Inc., MA, USA) as previously described (Deng et al., 2015) .
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Ring test
Catalepsy was assessed using the ring test as previously described (Pertwee, 1972) . Immobility latency (s) that the animal spent motionless on the ring during a 5-min observation period was recorded.
Statistical analyses
Analysis of variance ( This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. or chronic vehicle (Fig. 5B) , suggesting that rimonabant-induced scratching in the vehicle-treated mice is mediated by CB 1 receptors.
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This article has not been copyedited and formatted. The final version may differ from this version. failed to attenuate paclitaxel-evoked allodynia relative to vehicle (P>0.84 for both modalities) in CB 1 KO mice (Fig. 7A-B) . Medium dose CP55,940 (1 mg/kg i.p.) partially attenuated paclitaxel-induced mechanical and cold hypersensitivities in CB 1 KO mice (P<0.01, Fig. 7A-B ). Higher doses of CP55,940 (3 or 10 mg/kg i.p.) fully reversed paclitaxel-induced mechanical and cold allodynia in CB 1 KO mice relative to vehicle (P<0.0001) and normalized responses to pre-paclitaxel levels (P>0.49, Fig. 7A-B) . WT mice treated with CP55,940 (3 mg/kg i.p.) exhibited severe catalepsy and thus were not used for the assessments of mechanical and cold allodynia.
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Discussion
Psychotropic effects have represented significant hurdles for advancing cannabinoids as pharmacotherapies (Dhopeshwarkar and Mackie, 2014) . Tolerance develops to CB 1 -mediated locomotor effects of CP55,940 and Interestingly, we unmasked a novel CB 2 -mediated component of CP55,940-induced antiallodynic effects through the use of CB 1 KO mice. CP55,940 at a dose of 3 mg/kg i.p.
(i.e., ten times higher than the dose producing CB 1 -mediated pharmacological effects in WT mice) activated CB 2 receptors and produced anti-allodynic effects in CB 1 KO mice.
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This article has not been copyedited and formatted. The final version may differ from this version. (Fox et al., 2001; Lim et al., 2003) , and suppress central sensitization in spinal dorsal horn neurons (Chapman, 2001) in neuropathic pain models.
CP55,940 at a ten-fold higher dose (3 mg/kg/day i.p.) produced severe catalepsy in WT but not CB 1 KO mice, consistent with previous reports on CB 1 -mediated catalepsy (Lichtman and Martin, 1997; Oviedo et al., 1993) . Cataleptic effects of CP55,940 were absent in CB 1 KO mice, we therefore used CP55,940 in conjunction with CB 1 KO mice as a tool for studying CB 2 -mediated signaling in isolation from CB 1 receptors (i.e., without the confounding effects of the drug on motor behavior). CP55,940 administered at the higher dose produced anti-allodynic effects in CB 1 KO mice. Moreover, these antiallodynic effects were blocked by the CB 2 antagonist AM630, suggesting that CP55,940
This article has not been copyedited and formatted. The final version may differ from this version. (Scott et al., 2004) . Activation of spinal and/or peripheral CB 2 receptors by CB 2 agonists, following acute or chronic administration, suppresses neuropathic pain (Deng et al., 2015; Hsieh et al., 2011; Landry et al., 2012; Yamamoto et al., 2008) . CB 2 agonists are likely to suppress neuropathic nociception by down-regulation of pro-inflammatory cytokines and chemokines (Deng et al., 2015; Eljaschewitsch et al., 2006; Klegeris et al., 2003; Wilkerson et al., 2012) as well as inhibition of central sensitization (Elmes et al., 2004; Nackley et al., 2004) .
CP55,940 binds with similar affinity to mouse CB 1 (Kd = 0.77 nM) (Abood et al., 1997) and CB 2 receptors (Kd = 0.73 nM) (Griffin et al., 2000) in in vitro assays. This relationship also holds for human CB 1 and CB 2 receptors (Felder et al., 1995) .
Interestingly, in our in vivo study, a ten-fold higher dose of CP55,940 was required to produce CB 2 -mediated anti-allodynic efficacy relative to CB 1 -mediated anti-allodynic efficacy. Thus, low dose CP55,940 preferentially engaged CB 1 -mediated processes, consistent with the high expression levels of CB 1 compared to CB 2 in the CNS (Galiegue et al., 1995; Marsicano and Lutz, 1999; Onaivi et al., 2006; Schatz et al., 1997) . At a higher dose, CP55,940 suppresses pain by triggering CB 2 signaling in addition to the CB 1 -mediated mechanism. Indeed, in an inflammatory pain model, CB 2 receptors are involved in the peripheral antihyperalgesic actions of a mixed CB 1 /CB 2 agonist WIN55,212-2, when administered locally in the paw, under conditions in which central CB 1 receptors would not be activated (Nackley et al., 2003) . We postulate that the higher
This article has not been copyedited and formatted. The final version may differ from this version. As expected, CP55,940 produced hypothermia in WT, but not CB 1 KO mice (McGregor et al., 1996; Rawls et al., 2002; Varvel et al., 2005) . By contrast, chronic CP55,940, at a dose that produced CB 2 -mediated anti-allodynic efficacy, failed to decrease body temperature in CB 1 KO mice, documenting that prolonged activation of CB 2 receptors does not result in hypothermia (Amenta et al., 2012; Elliott et al., 2011; Kinsey et al., 2011; Malan et al., 2001; Valenzano et al., 2005; Yao et al., 2009) . Chronic CP55,940-treated WT, but not CB 1 KO mice, showed profound withdrawal signs when challenged with the CB 1 antagonist rimonabant, suggesting precipitation at CB 1 receptors produces withdrawal symptoms (Aceto et al., 1996; Cook et al., 1998; Lichtman et al., 2001; Rubino et al., 1998; Tsou et al., 1995) . Interestingly, although rimonabant challenge preferentially increased scratching bouts in mice treated with CP55,940 compared to vehicle, rimonabant-elicited scratching was notably absent in CB 1 KO mice, demonstrating that antagonist-induced scratching [analogous to pruritis (Proietto et al., 2010) ] in the absence of chronic cannabinoid dosing is mediated by CB 1 receptors, rather than an off-target effect of rimonabant. Our studies are the first to evaluate possible signs of physical dependence in animal pain models associated with repeated systemic activation of CB 2 receptors (present data and (Deng et al., 2015) ). These studies provide strong evidence that activation of CB 2 receptors produce substantial anti-allodynic efficacy independent of CB 1 receptors.
This article has not been copyedited and formatted. The final version may differ from this version. One of the common features of GPCRs is that prolonged exposure to their agonists lead to the development of tolerance (Martin et al., 2004; Taylor and Fleming, 2001) . A striking observation of our study was that tolerance to the therapeutic effects of CP55,940 (0.3 mg/kg/day i.p.) occurred later than tolerance to its psychotropic effects.
Our results, along with published reports (Bass and Martin, 2000; McKinney et al., 2008; Nguyen et al., 2012) , suggested that the time course of tolerance may vary between different CB 1 -mediated pharmacological effects (e.g., analgesia, hypothermia, hypoactivity). Interestingly, using the same mouse model of paclitaxel-induced neuropathy, complete tolerance developed to both antinoiceptive and hypothermic effects of the prototypical cannabinoid Δ 9 -THC over 8 days (Deng et al., 2015) . CP55,940 and Δ 9 -THC differ in potency at CB 1 receptors (Darmani et al., 2007; Wiley et al., 1995) and tolerance development (De Vry et al., 2004) . Ligand-dependent differences in tolerance development for different pharmacological effects may be attributed to the different signaling pathways recruited by CB 1 receptors (Martin et al., 2004) and regionally specific differences in receptor density and/or efficacy (McKinney et al., 2008; Oviedo et al., 1993) . For instance, CP55,940 and Δ 9 -THC differ in CB 1 receptor internalization (Hsieh et al., 1999) and inhibition of adenylyl cyclase activity (Breivogel et al., 1998; Childers and Deadwyler, 1996; Fan et al., 1996; Rubino et al., 2000a; Rubino et al., 2000b; Sim et al., 1995) , whereas these ligands act similarly with respect to other CB 1 signaling pathways, such as extracellular-signal-regulated kinase (ERK) activation (Daigle et al., 2008; Rubino et al., 2005) . More studies that correlate behavior observations and functional signaling pathways are needed to understand tolerance associated with CB 1 receptors. In addition to CB 1 -associated tolerance, the present report
This article has not been copyedited and formatted. The final version may differ from this version. also asked whether the high dose CP55,940 treatment in CB 1 KO mice would produce tolerance to CB 2 -mediated anti-allodynic effects. Notably, no decrement in CB 2 -mediated anti-allodynic effects was observed in CB 1 KO mice treated with daily administration of the high dose CP55,940, similar to previous reports with CB 2 -preferring agonists (Deng et al., 2015; Yao et al., 2009 ).
In conclusion, the present report demonstrated distinct roles of cannabinoid receptor subtypes in mediating the beneficial and adverse effects of CP55,940 in the animal model of paclitaxel-induced neuropathy. CP55,940 suppressed the maintenance of paclitaxel-induced neuropathic pain through both CB 1 -and CB 2 -dependent mechanisms.
CB 2 -mediated antinociceptive effects were engaged at doses approximately ten times higher than those required to produce CB 1 -mediated antinociception. On the other hand, CB 1 , but not CB 2 receptors were engaged in CP55,940-produced hypothermia, catalepsy, and cannabimimetic physical withdrawal. Our results further demonstrate that CB 2 receptors represent a potential therapeutic target for effectively and safely managing chemotherapy-induced neuropathic pain without unwanted effects.
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